Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer

Cancer Letters

Volumn 287, Issue 1, 2010, Pages 91-97

  Zhang, Hai Yan ^a   Sun, Hong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; Foxp3; Invasion; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; UROKINASE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; NF-KAPPA B; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

MAMMALIA;

EID: 72049096373     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.001     Document Type: Article

References (32)

1. Ozols R.F., Bookman M.A., and Connolly D.C. Focus on epithelial ovarian cancer. Cancer Cell 5 (2004) 19-24
2. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27 (2001) 68-73
3. Hori S., and Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 6 (2004) 745-751
4. Fonteno J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003) 330-336
5. Yisong Y.W., and Richard A.F. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445 15 (2007) 766-770
6. Karanikas V., Speletas M., Zamanakou M., et al. Foxp3 expression in human cancer cells. J. Transl. Med. 6 (2008) 19-26
7. Hinz S., Pagerols-Raluy L., Oberg H.H., et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 67 17 (2007) 8344-8350
8. Zuo T., Liu R.H., Zhang H.M., et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 117 12 (2007) 3765-3773
9. Zuo T., Wang L.Z., Morrison C., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129 (2007) 1275-1286
10. Egorina E.M., Sovershaev M.A., and Osterud B. In-cell western assay: a new approach to visualize tissue factor in human monocytes. J. Throm. Haemost. 4 3 (2006) 614-620
11. Dominik W., Anna M.W., Holger R., et al. The expression of the regulatory T cell specific Forkhead Box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 23 (2005) 8231-8236
12. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2003) 942-949
13. Katoh M., and Katoh M. Human FOX gene family. Int. J. Oncol. 25 5 (2004) 1495-1500
14. Jung H.Y., Park S.H., Yoo Y.D., et al. CDK2/4 regulates retinoic acid-induced G1 arrest in hepatocellular carcinoma cells. Hepatol. Res. 31 3 (2005) 143-152
15. Davidson B., Risberg B., Berner A., et al. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. Gynecol. Oncol. 83 2 (2001) 249-256
16. Zhong W., Peng J., He H., et al. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin. Invest. Med. 31 1 (2008) E8-E15
17. Reitmaier M., Rudlowski C., Biesterfeld S., et al. Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma. ZBL Gynakol. 122 7 (2000) 361-367
18. Fingar D.C., Salama S., Tsou C., et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 with 4EBP1/eIF4E. Genes Dev. 16 (2002) 1472-1487
19. Mabuchi S., Altomare D.A., Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. 13 14 (2007) 4261-4270
20. Mabuchi S., Altomare D.A., Connolly D.C., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 67 6 (2007) 2408-2413
21. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 9637 (2008) 449-456
22. Hashimoto I., Koizumi K., Tatematsu M., et al. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur. J. Cancer 4 7 (2008) 1022-1029
23. Cao C., Subhawong T., Albert J.M., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 66 20 (2006) 10040-10047
24. Sillanpää S., Anttila M., Voutilainen K., et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol. Oncol. 104 2 (2007) 296-303
25. Sillanpää S., Anttila M., Suhonen K., et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol. 28 5 (2007) 280-289
26. Curran S., and Murray G.I. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur. J. Cancer 36 (2000) 1621-1630
27. Belotti D., Paganoni P., Manenti L., et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63 17 (2003) 5224-5229
28. Ogawa K., Chen F., Kuang C., et al. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappa B site. Biochem. J. 381 Pt 2 (2004) 413-422
29. Altinoz M.A., and Korkmaz R. NF-kappa B, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 51 4 (2004) 239-247
30. Fujioka S., Sclabas G.M., Schmidt C., et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene 22 (2003) 1365-1370
31. Kobayashi H., Suzuki M., Kanayama N., et al. A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation. Clin. Exp. Metast. 21 2 (2004) 159-166
32. Duffy M.J., and Duggan C. The urokinase plasminogen activator system: a rich source of tumor markers for the individualized management of patients with cancer. Clin. Biochem. 37 (2004) 541-548